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Does warfarin prevent 
deep venous thrombosis 
in high-risk patients?
■ EVIDENCE-BASED ANSWER
Warfarin (Coumadin) is effective in preventing
deep venous thrombosis (DVT) among patients
with a  history of DVT. Conventional dosing and
longer durations are the most effective, but the
ideal length of therapy is unknown (strength of
recommendation [SOR]: A, based on large ran-
domized controlled trials and meta-analysis). 
Warfarin is useful in preventing DVT in patients
with cancer, specifically those treated with chemo-
therapy (SOR: B, based on small randomized 
Macrolides: comparison studies
Cost for course of
Antibiotic Response rates* (%) Side-effect rates† (%) therapy in adult‡
Erythromycin1–4 77–100 10–59 $11 (500 mg #40)
Clarithromycin5–7 88–94 5–31 $76 (250 mg #20)
Azithromycin1–4,7 87–100 0–14 $57 (250 mg #6)
*Response rates of pneumonia due to M pneumoniae and C pneumoniae.
† In community-acquired pneumonia treated with macrolide as single agent.
‡ Prices from www.drugstore.com.
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■ CLINICAL COMMENTARY
Lower respiratory infections—
a number of problematic decisions
You face several problematic decisions when
treating a patient with a lower respiratory
infection. First, is this pneumonia or just
bronchitis? Clinical findings can be confus-
ing, and a chest film is helpful.12 If pneumonia
is likely, you consider hospitalization, and
prescribe antibiotics, usually without know-
ing the pathogen.
Because they cover both typical and atypical
pathogens, macrolides (or doxycycline) are
generally recommended, with cephalosporins
to be added for higher-risk patients. (Quinolones
are an alternative to this combination.) Finally,
if you choose a macrolide, you face yet another
decision without a clear answer: which one to
use? All macrolides appear to be equally effec-
tive, so the choice depends on cost balanced
against convenience and side effects. 
David Mouw, MD, Mountain Area AHEC, Asheville, NC
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controlled trials). Warfarin may be effective in pre-
venting DVT in immobilized patients such as those
with trauma, spinal cord injury, or stroke (SOR: B,
based on an underpowered randomized controlled
trial and uncontrolled studies).
■ EVIDENCE SUMMARY
Warfarin, at both low and conventional doses, has
been shown to be effective in preventing recur-
rence of DVT. A large, 4-year placebo-controlled
randomized controlled trial showed that long-term
low-dose warfarin (international normalized ratio
[INR], 1.5–1.9) was more effective than placebo
for prevention of DVT (hazard ratio=0.36; 95%
confidence interval [CI], 0.19–0.67).1
A double-blind randomized controlled trial of
738 patients demonstrated that conventional-
intensity warfarin therapy (INR=2.0–3.0) was
more effective than low-intensity therapy
(INR=1.5–1.9) in prevention of recurrent DVT.
There were 1.9 vs 0.7 DVTs per 100 person-years
in the low-intensity vs conventional-intensity ther-
apy groups (hazard ratio=2.8; 95% CI, 1.1–7.0;
number needed to treat [NNT]=37). No significant
difference was seen in the frequency of bleeding
complications between the groups.2 This and other
studies suggest that low-intensity warfarin therapy
reduces the relative risk of thrombosis by about
75%, and conventional-intensity therapy reduces
this risk by over 90%.2
Several studies have examined the duration of
warfarin therapy. A meta-analysis found treatment
with warfarin for 12 to 24 weeks decreased DVT
recurrence compared with 2- to 6-week regimens
(relative risk [RR]=0.60; 95% CI, 0.45–0.79;
NNT=21).3 A multicenter randomized controlled
trial found extending warfarin treatment for 12
months vs 3 months resulted in a 95% relative risk
reduction (RRR) in risk of DVT recurrence (95%
CI, 63–99; NNT=5).4 A multicenter randomized
trial showed similar results, but risk for recurrence
was the same after treatment was stopped, regard-
less of the length of treatment.5
In patients with cancer, warfarin was shown
to be more effective than placebo in prevention of
DVT. In a trial of 311 breast cancer patients
receiving chemotherapy, treatment with very-low-
dose warfarin (INR=1.3–1.9) decreased thrombot-
ic events compared with placebo, with no increase
in bleeding complications (RRR=85%; P=.031;
NNT=27).6 A later cost analysis showed that very-
low-dose warfarin can be used in prevention of
DVT in breast cancer patients on chemotherapy
without an increase in health care costs.7
Although immobilized patients are at high risk
for DVT, no randomized controlled trials exist for
the use of warfarin in these patients. A few small
studies suggest that warfarin reduces DVT rates
in spinal-cord-injured patients.8 A small trial 
randomized stroke patients undergoing rehabili-
tation to placebo or fixed 1- or 2-mg doses of 
warfarin. This underpowered study showed a
nonsignificant decrease in the risk of develop-
ment of DVT (RR=0.39; 95% CI, 0.13–1.37).8
■ RECOMMENDATIONS FROM OTHERS
The 6th American College of Chest Physicians
Consensus Conference on Antithrombotic Therapy
makes these recommendations:
9
Prior DVT: Oral anticoagulation therapy
(INR=2.0–3.0) is indicated for at least 3 months
for patients with proximal DVT or for at least 6
months in those with idiopathic proximal vein
thrombosis or recurrent venous thrombosis.
Indefinite anticoagulation is indicated for
patients with more than 1 episode of idiopathic
proximal vein thrombosis or pulmonary embolus.
Malignancy: Indefinite anticoagulation (INR=
2.0–3.0) is indicated for patients with thrombo-
sis complicating malignancy. Prophylaxis with
low-intensity warfarin in ambulatory patients
with cancer to prevent initial DVT warrants fur-
ther study.
Acute spinal cord injuries: Low-molecular-
weight heparin or switch to full-dose oral anti-
coagulation (INR=2.0–3.0) for the duration of
the rehabilitation phase.
Rebecca L. Spaulding, MD, M. Lee Chambliss, MD,
MSPH, Moses Cone Family Medicine Residency, Greensboro NC;
Leslie Mackler, MLS, Moses Cone Health System, Greensboro NC
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■ CLINICAL COMMENTARY
Routine prophylaxis dramatically
reduces DVT cases
I can clearly recall the dramatic reduction in the
number of our patients who developed DVT when
our orthopedic colleagues embraced routine pro-
phylaxis for the high-risk surgical patients with
hip surgery and knee replacements. This answer
indicates that we may also be able to reduce the
risk of DVT in our high-risk nonsurgical patients
with previous DVT or breast cancer. Note that
much of the evidence is based on the use of low-
dose and very-low-dose warfarin. This may help
mitigate our fear of substituting bleeding compli-
cations for the prevention of clots.
John P. Langlois, MD, MAHEC Family Practice
Residency, Asheville, NC
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Do antibiotics 
improve outcomes 
in chronic rhinosinusitis?
■ EVIDENCE-BASED ANSWER
For children, antibiotics do not appear to improve
short-term (3–6 weeks) or long-term (3 months)
outcomes of chronic rhinosinusitis (strength of
recommendation [SOR]: A, randomized controlled
trials). No adequate placebo-controlled trials have
been performed in adults. Two consensus state-
ments report that 10 to 21 days of antibiotics
active against organisms producing beta-lacta-
mase might be beneficial in some cases (SOR: C).
■ EVIDENCE SUMMARY
The American Academy of Otolargynology–Head
and Neck Surgery defines chronic rhinosinusitis as
the persistence of 2 major or 1 major and 2 minor
criteria lasting at least 12 weeks (Table).1 The
other categories of rhinosinusitis are acute (symp-
toms lasting <3 weeks) and subacute (symptoms
lasting 3–12 weeks). 
Two placebo-controlled trials have evaluated
antibiotic treatment of chronic rhinosinusitis in chil-
dren. In 1 study, 141 children with chronic rhinosi-
nusitis were randomly assigned to 1 of 4 treatment
arms: saline nose drops; xylometazoline (Otrivin)
drops with oral amoxicillin 3 times daily; surgical
drainage; or surgical drainage, amoxicillin 3 times
daily and xylometazoline drops.2 Outcomes were
resolution of purulent rhinitis, no purulent drainage
on exam, and no abnormalities of maxillary sinus on
x-ray. The absence of all 3 findings constituted cure.
At 6 weeks there was a non-statistically significant
higher resolution in the fourth group, but by 26
weeks the groups were indistinguishable. At 6
weeks, 53%, 50%, 55%, and 79% of each group,
respectively, were cured. These results increased to
69%, 74%, 69%, and 64% at 26 weeks.
Another study randomized 79 children with
chronic sinusitis to treatment with cefaclor vs
placebo following antral washout.3 Measured
